Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.3
2.4
Journals
Medicina
Special Issues
Progression of Chronic Renal Failure
share announcement

Progression of Chronic Renal Failure

A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Urology & Nephrology".

Deadline for manuscript submissions: closed (30 November 2022) | Viewed by 5890

Special Issue Editor

Dr. Takafumi Ito

E-Mail Website
Guest Editor
Division of Nephrology, Shimane University Hospital, 89-1 Enyacho, Izumo 693-8501, Japan
Interests: CKD; glomerulonephritis; nephrotic syndrome; ADPKD; psychonephrology; geriatrics; therapeutic apheresis

Special Issue Information

Dear Colleagues,

The number of patients with chronic kidney disease (CKD) is increasing worldwide, and its causes are closely related to lifestyle-related diseases such as hypertension, diabetes, and dyslipidemia, in addition to diseases of the kidney itself such as chronic glomerulonephritis and nephrosclerosis and aging. In addition, as CKD progresses, not only does dialysis therapy become necessary, but cardiovascular diseases such as myocardial infarction and stroke can also develop, which ultimately affect life expectancy.

Under these circumstances, it is of the utmost importance to elucidate the precise mechanism of the progression of CKD and the "development of novel treatments including pharmacological approach to control the disease progression", as well as to take measures against CKD in the community.

In this Special Issue, we welcome submissions that include basic research, such as "research on elucidation of the mechanism of progression of CKD" and "development of drugs to control the progression of CKD", and also clinical research on measures against CKD such as "promotion and awareness of CKD" and "establishment of a system for cooperation in medical care."

Dr. Takafumi Ito
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • chronic kidney disease
  • cardiovascular disease
  • mechanism of progression of CKD
  • development of drugs
  • measures against CKD

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

12 pages, 2689 KiB  
Article
The Beneficial Effect of Personalized Lifestyle Intervention in Chronic Kidney Disease Follow-Up Project for National Health Insurance Specific Health Checkup: A Five-Year Community-Based Cohort Study
by Hidemi Takeuchi, Haruhito A. Uchida, Katsuyoshi Katayama, Natsumi Matsuoka-Uchiyama, Shugo Okamoto, Yasuhiro Onishi, Yuka Okuyama, Ryoko Umebayashi, Kodai Miyaji, Akiko Kai, Izumi Matsumoto, Keiko Taniguchi, Fukiko Yamashita, Tsutomu Emi, Hitoshi Sugiyama and Jun Wada
Medicina 2022, 58(11), 1529; https://doi.org/10.3390/medicina58111529 - 26 Oct 2022
Viewed by 1623
Abstract
Background and Objectives: Mimasaka city is a relatively small city with a population of 28,381, and an aging rate (≥65 years old) of 38.9%, where only one nephrology clinic is available. Since 2013, the city has conducted its own unique lifestyle intervention for [...] Read more.
Background and Objectives: Mimasaka city is a relatively small city with a population of 28,381, and an aging rate (≥65 years old) of 38.9%, where only one nephrology clinic is available. Since 2013, the city has conducted its own unique lifestyle intervention for the participants of the National Health Insurance specific medical health checkup, aiming to prevent the progression of chronic kidney disease (CKD) severity. Materials and Methods: The persons in National Health Insurance specific medical health checkup (40–74 years old) conducted in Mimasaka city in 2013, with eGFR less than 50 mL/min/1.73 m² or 50–90 mL/min/1.73 m² with urine dipstick protein 1+ or more, were registered for the CKD follow-up project, as high-risk subjects for advanced renal dysfunction. Municipal workers directly visited the subjects’ homes to provide individual health guidance and encourage medical consultation. We aimed to examine the effect of home-visit intervention on the changes of renal function and related factors until 2017. Results: The number of the high-risk subjects who continuously received the health checkup until 2017 was 63, and only 23 (36.5%) visited a medical institution in the first year. The eGFR decreased by only 0.4 mL/min/1.73 m²/year, and the subjects with urinary protein 1+ or higher decreased significantly from 20 (31.7%) to 9 (14.3%) (p = 0.034) in the high-risk subjects. The changes in eGFR and urinary protein was almost in the same fashion regardless of their medical institution visits. Next, we examined the effects of various factors on ΔeGFR, the changes of eGFR from 2013 to 2017, by multivariate linear regression analysis. The effects of medical institution visit were not significant, and the degree of urinary protein (coefficient B: 4.503, β: 0.705, p < 0.001), age (coefficient B: 4.753, β: 0.341, p = 0.004), and smoking (coefficient B: 5.878, β: 0.295, p = 0.031) had independent significant effects, indicating that they were the factors exacerbating the decrease in eGFR from the baseline. Conclusions: The personalized lifestyle intervention by home-visit in CKD follow-up project showed the possibility of beneficial effects on the deterioration of renal function. This may be an efficient method to change behavior in a small community with limited medical resources. Full article
(This article belongs to the Special Issue Progression of Chronic Renal Failure)
►▼ Show Figures

Figure 1

Review

Jump to: Research

13 pages, 1055 KiB  
Review
Recent Progresses in Non-Dialysis Chronic Kidney Disease Patients with Hyperkalemia: Outcomes and Therapeutic Strategies
by Ruixue Tian, Rongshan Li and Xiaoshuang Zhou
Medicina 2023, 59(2), 353; https://doi.org/10.3390/medicina59020353 - 13 Feb 2023
Viewed by 3703
Abstract
Chronic kidney disease (CKD) affects about 10% of the world’s population. Hyperkalemia is a life-threatening complication in patients with CKD, as it is associated with adverse cardiovascular and kidney outcomes. There are still many challenges and questions to address to improve the currently [...] Read more.
Chronic kidney disease (CKD) affects about 10% of the world’s population. Hyperkalemia is a life-threatening complication in patients with CKD, as it is associated with adverse cardiovascular and kidney outcomes. There are still many challenges and questions to address to improve the currently available therapeutic strategies to treat hyperkalemia, such as how to approach the emergency management of hyperkalemia. In recent years, in addition to novel oral potassium binders, great progress has been made in the application of novel kidney protective strategies, such as mineralocorticoid receptor antagonists and sodium–glucose cotransporter 2 inhibitors (SGLT2i) in hyperkalemia therapy. This review will discuss the recent advances from clinical trials in the effective management of hyperkalemia in non-dialysis CKD patients, enhancing the knowledge of physicians and internists concerning these newer agents and providing a helpful reference for clinical practice. Full article
(This article belongs to the Special Issue Progression of Chronic Renal Failure)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop